Nestle India Faces FSSAI Probe Over Infant Nutrition Claims

Nestle India is facing legal action from the Food Safety and Standards Authority of India (FSSAI) following allegations of regulatory non-compliance regarding its infant nutrition product line. The regulator has raised concerns over promotional claims and the nutritional composition of the company’s offerings, marking a significant development for the multinational’s operations in the Indian market.

According to reports, the FSSAI has contested specific marketing assertions made by Nestle, including claims related to the inclusion of “5 HMOs” (Human Milk Oligosaccharides) and the protein profiles of its infant formulas. The regulator has deemed these promotional statements inappropriate under current food safety standards. Furthermore, laboratory testing of a specific infant formula sample identified a deficiency in biotin content, leading the authority to categorize the product as substandard.

In response to these developments, Nestle India has maintained that its products strictly adhere to all applicable national regulations and possess the necessary official approvals. The company has emphasized its commitment to quality and compliance, noting that its infant nutrition portfolio undergoes rigorous internal and external safety assessments.

For institutional investors and market analysts, this regulatory friction highlights the heightened oversight within India’s consumer goods sector. As the FSSAI continues to tighten enforcement regarding health claims and nutritional standards, companies in the FMCG space may face increased operational risks and potential impacts on marketing strategies. This case underscores the importance of stringent regulatory alignment for multinational corporations navigating the evolving landscape of India’s food safety framework.